Management of unhealthy opioid and polysubstance use among patients in primary care settings. FY22. POP 9/15/22 - 9/14/27.
Active Awarded Last action
- Contract number
- 75N95022F00003
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,299,926
Award facts
- Contract value 100% obligated
- $1,299,926.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,299,926 |
About this award
This is a $1,299,926.00 federal contract awarded by the Department of Health and Human Services' National Institutes of Health's National Institute on Drug Abuse (NIDA) to The Emmes Company LLC, a for-profit limited liability company. The contract is for the management of unhealthy opioid and polysubstance use among patients in primary care settings over a 5-year period from September 2022 to September 2027. This appears to be a delivery order contract of the cost-plus-fixed-fee type, with no set-aside designation.
The Emmes Company is an experienced provider of clinical research services to federal agencies, particularly NIDA and other NIH institutes. The company has held multiple indefinite delivery contracts with NIH, including a $46 million CTN Clinical Coordinating Center for NIDA's Clinical Trials Network. In this role, Emmes will likely provide data management, statistical analysis, protocol development, and other operational support for the primary care-focused opioid/polysubstance use research program.
Quick answers
Who was awarded contract 75N95022F00003?
75N95022F00003 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2022.
How much is contract 75N95022F00003 worth?
The government has obligated $1,299,926 on 75N95022F00003.
Is contract 75N95022F00003 an order under another contract?
Yes. 75N95022F00003 is a delivery order under 75N95020D00012, an indefinite delivery contract.
Was contract 75N95022F00003 competed?
The extent of competition for 75N95022F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award